Treatment With Crizotinib Single Patient Expanded Access IND 134375

NCT03085186

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Inflammatory Myofibroblastic Tumour
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Not applicable as Expanded Access only includes one patient

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Inflammatory Myofibroblastic TumourTreatment With Crizotinib Single Patient Expanded Access IND 134375
NCT03085186
Male
2 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Treatment With Crizotinib Single Patient Expanded Access IND 134375
Official Title Treatment With Crizotinib Single Patient Expanded Access IND 134375
Brief Summary

Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen.

Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.

Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Inflammatory Myofibroblastic Tumour
Intervention Drug: Crizotinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status No longer available
Eligibility Criteria

Inclusion Criteria:

  • This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour

Exclusion Criteria:

  • Not applicable as Expanded Access only includes one patient
Sex/Gender
Sexes Eligible for Study:Male
Ages 2 Years to 2 Years   (Child)
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03085186
Other Study ID Numbers PRO17030033
Responsible Party Jean M. Tersak, M.D., University of Pittsburgh
Study Sponsor Jean M. Tersak, M.D.
Collaborators Pfizer
Investigators Not Provided
PRS Account University of Pittsburgh
Verification Date August 2017